Código QR (código de barras bidimensional)

Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation

IntroductionCDK4/6 inhibitors are the first-line treatment for HR+/HER2- advanced breast cancer. Despite their clinical benefit, they can increase healthcare expenditure. To date, there is no thorough comparison among the three approved CDK4/6 inhibitors in terms of their cost-effectiveness.Objectiv...

ver descrição completa

Na minha lista:
Principais autores: Shereen Elazzazy, Nour Hisham Al-Ziftawi, Mohamed Izham Mohamed Ibrahim, Salha Bujassoum, Anas Hamad
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2024-07-01
coleção:Frontiers in Oncology
Assuntos:
breast cancer
palbociclib
ribociclib
abemaciclib
cost-effectiveness
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2024.1413676/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados